Malignant Esophageal Neoplasm

cancer

Identifier: CI-CAN-00001127
Entity page: /cancer/malignant-esophageal-neoplasm ↗
Edges: 2,217

Neighbours: 16 genes1 variants18 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Esophageal Neoplasm approved for …APPROVED_FOR9 of 6
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Malignant Esophageal Neoplasm	1	Regulatory	openfda	graph →
← approved for	Nivolumabmonoclonal_antibody	supports	FDA ORIG

Malignant Esophageal Neoplasm predicts response to …PREDICTS_RESPONSE_TO2 of 2
in context · predicts response to	GNAS c.393T>CSNV → predicts response to Cisplatin	resistance	B	Malignant Esophageal Neoplasm	1	Curated	civic	graph →
in context · predicts response to	GNAS c.393T>CSNV → predicts response to Fluorouracil	resistance	B	Malignant Esophageal Neoplasm	1	Curated	civic	graph →

Malignant Esophageal Neoplasm predicts response to …PREDICTS_RESPONSE_TO2 of 2

in context · predicts response to

GNAS c.393T>CSNV → predicts response to Cisplatin

resistance

Malignant Esophageal Neoplasm

Curated

Malignant Esophageal Neoplasm investigated for …INVESTIGATED_FOR2 of 2
← investigated for	Cisplatinsmall_molecule	supports	B	Malignant Esophageal Neoplasm	1	Curated	civic	graph →
← investigated for	Fluorouracilsmall_molecule	supports	B	Malignant Esophageal Neoplasm	1	Curated	civic	graph →

Malignant Esophageal Neoplasm altered in cohorts of …ALTERED_INderived15 of 136show all (up to 200)
← altered in cohorts of	TP53 167 / 185 cases (90 %) · ssm · TCGA-ESCA · largest of 7 cohorts	—	—	Esophageal Carcinoma	7	Observed	gdc	graph →
← altered in cohorts of	MYC 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TG 138 / 185 cases (75 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KCNQ3 135 / 185 cases (73 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDKN2A 134 / 185 cases (72 %) · ssm · TCGA-ESCA · largest of 3 cohorts	—	—	Esophageal Carcinoma	3	Observed	gdc	graph →
← altered in cohorts of	GSDMC 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	LRATD2 134 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDKN2B 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EFR3A 133 / 185 cases (72 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCN4 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHLA1 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KHDRBS3 132 / 185 cases (71 %) · ssm · TCGA-ESCA	—	—	Esophageal Carcinoma	1	Observed	gdc	graph →

Malignant Esophageal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)
→ investigated in trials for	Cisplatinsmall_molecule 141 trials (29 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	141	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 121 trials (37 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	121	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall_molecule 120 trials (27 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	120	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 75 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	75	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 66 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 64 trials (25 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 62 trials (24 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	62	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 57 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 48 trials (15 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 47 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 40 trials (24 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 34 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 32 trials (18 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Camrelizumabmonoclonal antibody 28 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 28 trials (14 active) · roll-up of the cancer and its descendants	—	—	Malignant Esophageal Neoplasm	28	Observed	clinicaltrials	graph →

Malignant Esophageal Neoplasm studied in …STUDIED_INderived10 of 1,926show all (up to 200)
→ studied in	NCT04415853Phase 3 · recruiting Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer · condition mapped CURATED_EXACT · 1,926 trials mapped (660 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05048368Phase 1 · withdrawn Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · condition mapped CURATED_EXACT · 1,926 trials mapped (660 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 1,926 trials mapped (660 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ALIAS · 1,926 trials mapped (660 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 1,926 trials mapped (660 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07519655Phase 1 · recruiting Phase 1 Study of PF-08046033 in Advanced Solid Tumors · condition mapped CURATED_EXACT · 1,926 trials mapped (660 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07733180Phase 2 · recruiting A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC · condition mapped CURATED_BROADER · 1,926 trials mapped (660 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06005493Phase 1/Phase 2 · recruiting Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,926 trials mapped (660 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06172478Phase 2 · recruiting A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors · condition mapped CURATED_EXACT · 1,926 trials mapped (660 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 1,926 trials mapped (660 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains